K. Jéhannin-ligier, Projection de l'incidence et de la mortalité par cancer en France métropolitaine en 2017. Rapport technique, p.80, 2017.

K. T. Bui, W. A. Cooper, S. Kao, and M. Boyer, Targeted Molecular Treatments in Non-Small Cell Lung Cancer : A Clinical Guide for Oncologists, J Clin Med, vol.7, issue.8, p.192, 2018.

J. Cadranel, A. M. Ruppert, M. Beau-faller, and M. Wislez, Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma, Crit Rev Oncol Hematol, vol.88, pp.477-493, 2013.

J. Mazières, Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort, Ann Oncol, vol.27, issue.2, pp.281-286, 2016.

D. Corte and C. M. , Role and targeting of anaplastic lymphoma kinase in cancer, Mol Cancer, vol.17, issue.1, p.30, 2018.

A. T. Shaw, S. H. Ou, Y. J. Bang, D. R. Camidge, B. J. Solomon et al., Crizotinib in ROS1-rearranged non-small-cell lung cancer, The New England Journal of Medicine, vol.371, pp.1963-1971, 2014.

W. Pan, KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies, Oncotarget, vol.7, issue.7, pp.8373-88, 2016.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell. 2011, vol.144, issue.5, pp.646-674

R. Kalluri and R. A. Weinberg, The basics of epithelial-mesenchymal transition, J Clin Invest, vol.119, issue.6, pp.1420-1428, 2009.

C. S. Scanlon, E. A. Van-tubergen, R. C. Inglehart, D. Silva, and N. J. , Biomarkers of epithelialmesenchymal transition in squamous cell carcinoma, J Dent Res, vol.92, issue.2, pp.114-135, 2012.

T. Shibue and R. A. Weinberg, EMT, CSCs, and drug resistance: the mechanistic link and clinical implications, Nat Rev Clin Oncol, vol.14, issue.10, pp.611-629, 2017.

M. Dauphin, Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas, Lung Cancer, vol.81, issue.1, pp.117-122, 2013.

M. F. Emmons, F. Faiao-flores, and K. Smalley, The role of phenotypic plasticity in the escape of cancer cells from targeted therapy, Biochem pharmacol, vol.122, pp.1-9, 2016.

R. L. Yauch, Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients, Clin Cancer Res, vol.11, issue.24, pp.8686-8698, 2005.

H. R. Kim, Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation, Mol. Oncol, vol.7, pp.1093-1102, 2013.

W. Gou, CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib, Cancer Lett, vol.422, pp.19-28, 2018.

Y. Pekarsky, N. Zanesi, A. Palamarchuk, K. Huebner, and C. M. Croce, FHIT: from gene discovery to cancer treatment and prevention, Lancet Oncol, vol.3, issue.12, pp.748-754, 2002.

A. Joannes, Fhit regulates invasion of lung tumor cells, Oncogene, vol.29, issue.8, pp.1203-1213, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00453584

S. S. Suh, FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs, PLoS Genet, vol.10, issue.10, p.1004652, 2014.

A. Joannes, Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells, Mol Cancer Res, vol.12, issue.5, pp.775-783, 2014.